Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UNIVERSITY OF DUNDEE has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners but are concentrated within 1 distinct art unit. This structure indicates that while different individuals are reviewing the applications, they are all operating under the same art unit's guidelines and supervisory oversight.
ANNA GRACE KUCKLA is the busiest examiner, with 1 pending office action. Since there are 3 pending office actions and 3 distinct examiners, each examiner is responsible for exactly one case. This distribution ensures that no single examiner is overburdened with the university's portfolio, even though all 3 pending office actions are situated within the same 1 distinct art unit.
For a patent practitioner, the fact that 3 distinct examiners are working within 1 distinct art unit is significant. It suggests that while examiner-specific preferences will vary, the underlying technical standards will be consistent across the matters. The busiest examiner, ANNA GRACE KUCKLA, manages 1 pending office action, which is the same volume as the other examiners in this portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
| SPANGLER, JOSEPH RANKIN | 1 | 41.2% | +69.5% |
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694524 | PROTEIN DEGRADER | AGGARWAL, SAHIL CHANDER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720366 | TARGETED DEGRADATION OF ALPHA-SYNUCLEIN | SPANGLER, JOSEPH RANKIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18859690 | ANTI-INFECTIVE AGENTS | KUCKLA, ANNA GRACE | — |
| 18720366 | TARGETED DEGRADATION OF ALPHA-SYNUCLEIN | SPANGLER, JOSEPH RANKIN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859690 | ANTI-INFECTIVE AGENTS | KUCKLA, ANNA GRACE | — | §112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18720366 | TARGETED DEGRADATION OF ALPHA-SYNUCLEIN | SPANGLER, JOSEPH RANKIN | 1656 | §102§103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18694524 | PROTEIN DEGRADER | AGGARWAL, SAHIL CHANDER | — | §103§112DP | Non-Final OA | — | Pending | Mar 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial